Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cybin Inc. is a biotechnology company focused on developing psychedelic-based therapeutics for mental health disorders. Its proprietary drug development platform leverages novel compounds and delivery mechanisms, primarily targeting markets in North America and Europe for conditions such as depression and anxiety.
Cybin's business model revolves around the research and development of psychedelic compounds, which are undergoing clinical trials for various mental health conditions. The company aims to monetize its innovations through partnerships, licensing agreements, and eventual commercialization of successful therapies, benefiting from a growing acceptance of psychedelics in the healthcare sector.
Progress in clinical trials for lead compounds, particularly CYB003 for major depressive disorder
Regulatory approvals or advancements in psychedelic therapy legislation
Partnership announcements with larger pharmaceutical companies
Market sentiment regarding the psychedelic industry as a whole
Regulatory changes affecting the approval of psychedelic drugs
Technological disruption in drug development methodologies
Emergence of alternative therapies for mental health that could overshadow psychedelic treatments
Increased competition from other biotech firms in the psychedelic space
High cash burn rate with negative operating cash flow
Reliance on external funding for R&D activities
low - The demand for mental health therapeutics is relatively inelastic, but broader economic conditions can impact funding and investment in biotech.
Minimal impact as the company is currently not generating revenue and has no debt; however, higher rates could affect future capital raising efforts.
minimal
growth - Investors are likely attracted by the potential for high returns from innovative therapies in a burgeoning market.
high - The stock has shown significant price fluctuations, reflecting the speculative nature of biotech investments.
